Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part and have signed the consent form.
• People aged 18 to 75 years (any gender).
• People whose general health and ability to carry out daily activities is rated at a good to fairly good level on a standard oncology scale (ECOG score of 0 or 1).
• People with a life expectancy of at least 3 months.
• For the dose-finding stage: People with an advanced solid tumour confirmed by tissue or cell testing, where standard treatments have stopped working, caused intolerable side effects, or no standard treatment exists.
• For the dose-expansion stage: People with a locally advanced or metastatic solid tumour confirmed by tissue or cell testing, where curative surgery and/or curative radiotherapy combined with chemotherapy are not suitable options.
• People who have at least one tumour that can be measured using standard imaging criteria (RECIST v1.1).
• People with adequate bone marrow, liver, kidney, and other organ function (confirm with trial site for specific values).
• People who are able to have children (male or female) must agree to use highly reliable contraception with their partner during the trial and for at least 12 weeks after the last dose.

Who may not be able to join:

• People whose tumour sample contains small cell lung cancer components.
• People who have had two or more separate primary cancers within the past 5 years.
• People who have received chemotherapy within the past 3 weeks, or radiotherapy, biological therapy, hormone therapy, or immunotherapy within the past 4 weeks.
• People who have taken part in another trial using an unapproved investigational treatment within the past 4 weeks.
• People who have cancer that has spread to the brain, the lining around the brain or spinal cord, the brainstem, or is compressing the spinal cord.
• People who have had major surgery (not including biopsy) or a serious injury within the past 4 weeks, or who will need planned surgery during the trial.
• People with a history of a hole forming in the stomach or intestines (gastrointestinal perforation), complications with wound healing after surgery, or significant bleeding events.
• People who have received intravenous clot-dissolving treatment within the past 2 weeks (routine preventive blood-thinning medication is not included in this restriction).
• People who have received any vaccine within the past 4 weeks.
• People who have been taking steroid medicines throughout the body (systemic corticosteroids) within the past 14 days.
• People with seriously reduced lung function, a current or past lung condition involving scarring of the lung tissue (interstitial lung disease), a history of lung inflammation that needed steroid treatment, or who have had an entire lung removed.
• People with an active infection requiring treatment within the past 7 days.
• People with uncontrolled fluid build-up in body cavities (such as the chest or abdomen).
• People with serious heart or blood vessel conditions (confirm with trial site for specific details).
• People with a known allergy or sensitivity to the study drug or any of its ingredients.
• People with substance misuse issues or a mental or physical condition that could interfere with taking part in or completing the trial.
• People with a known dependence on alcohol or drugs.
• People who are pregnant, breastfeeding, or planning to become pregnant.

Important: Always verify eligibility with the trial site directly before applying.